Log in or Sign up for Free to view tailored content for your specialty!
Oncology News
Urinary metabolite panel effectively diagnosed HCC stage in West African patients
Urinary metabolites outperformed serum alpha fetoprotein in monitoring specific stages of hepatocellular carcinoma in patients in West Africa, according to new research data.
Liver cancer, disease mortality rates climbed in US in past 30 years
Liver cancer and liver disease mortality rates have increased over the last 3 decades in the United States, according to new findings.
Log in or Sign up for Free to view tailored content for your specialty!
Decompensated cirrhotic patients treated with entecavir without virologic response faced risk for HCC
Patients with decompensated cirrhosis who did not achieve virologic response with entecavir treatment were still at risk for hepatocellular carcinoma, compared with compensated patients, according to data from a new study.
Five things to know about cocamide DEA in personal care products
A legal agreement has been reached between some shampoo, lotion and other personal care products manufacturers to remove cocamide DEA from their products. The chemical, however, has not been banned, and more than 100 other companies have not yet resolved litigation brought by the Center for Environmental Health, a consumer advocacy group.
CA19-9, AFP levels predicted OS in liver transplant patients with hepatic carcinoma
Preoperative carbohydrate antigen 19-9 and alpha-fetoprotein levels measured in patients with hepatic carcinoma who underwent liver transplantation predicted overall survival and relapse-free survival rates, according to recent study data.
Adjuvant sorafenib failed to extend RFS in HCC
CHICAGO — Patients with hepatocellular carcinoma who underwent surgical resection or local ablation experienced similar rates of recurrence when treated with adjuvant sorafenib or placebo, according to results of a randomized phase 3 study presented at the 2014 ASCO Annual Meeting.
FDA grants CF102 orphan drug status to treat HCC in phase 2 trial
The FDA has granted orphan drug status to Can-Fite BioPharma for CF102 to treat advanced liver cancer in a phase 2 multinational clinical trial, according to a press release.
Diabetes increased risk for HCC mortality in middle-aged, elderly patients
Middle-aged and elderly Taiwanese patients with diabetes mellitus had an increased risk for death from hepatocellular carcinoma, according to new study results.
NASH expected to top indications for liver transplantation in HCC patients
Nonalcoholic steatohepatitis is the most rapidly progressing indication for liver transplantation among patients with hepatocellular carcinoma, a recent study determined.
Area poverty rate linked to incidence of certain cancers
Incidence of certain cancers in specific neighborhoods varied considerably based on the area’s poverty level, according to study results.
-
Headline News
NIH finds neuroscience director engaged in research misconduct
September 26, 20241 min read -
Headline News
Q&A: Phone app uses AI technology to personalize allergy forecasts
September 25, 20243 min read -
Headline News
FDA grants fast track designation to brepocitinib for noninfectious uveitis
September 25, 20241 min read
-
Headline News
NIH finds neuroscience director engaged in research misconduct
September 26, 20241 min read -
Headline News
Q&A: Phone app uses AI technology to personalize allergy forecasts
September 25, 20243 min read -
Headline News
FDA grants fast track designation to brepocitinib for noninfectious uveitis
September 25, 20241 min read